IL145816A0 - Pharmaceutical compositions of erythropoietin - Google Patents

Pharmaceutical compositions of erythropoietin

Info

Publication number
IL145816A0
IL145816A0 IL14581600A IL14581600A IL145816A0 IL 145816 A0 IL145816 A0 IL 145816A0 IL 14581600 A IL14581600 A IL 14581600A IL 14581600 A IL14581600 A IL 14581600A IL 145816 A0 IL145816 A0 IL 145816A0
Authority
IL
Israel
Prior art keywords
erythropoietin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IL14581600A
Other languages
English (en)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL145816A0 publication Critical patent/IL145816A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL14581600A 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin IL145816A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12859699P 1999-04-09 1999-04-09
US09/545,479 US6696056B1 (en) 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin
PCT/US2000/009414 WO2000061169A1 (en) 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin

Publications (1)

Publication Number Publication Date
IL145816A0 true IL145816A0 (en) 2002-07-25

Family

ID=22436082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14581600A IL145816A0 (en) 1999-04-09 2000-04-07 Pharmaceutical compositions of erythropoietin

Country Status (27)

Country Link
US (2) US6696056B1 (xx)
EP (1) EP1181036B1 (xx)
JP (1) JP2002541208A (xx)
KR (1) KR100740794B1 (xx)
CN (1) CN1165339C (xx)
AR (1) AR029623A1 (xx)
AT (1) ATE401908T1 (xx)
AU (1) AU775041B2 (xx)
BG (1) BG106046A (xx)
BR (1) BR0010665A (xx)
CA (1) CA2369444C (xx)
CY (1) CY1108418T1 (xx)
DE (1) DE60039598D1 (xx)
DK (1) DK1181036T3 (xx)
ES (1) ES2308978T3 (xx)
HK (1) HK1041445B (xx)
HU (1) HUP0201068A3 (xx)
IL (1) IL145816A0 (xx)
MX (1) MXPA01010208A (xx)
NO (1) NO20014893L (xx)
NZ (1) NZ515380A (xx)
PL (1) PL203797B1 (xx)
PT (1) PT1181036E (xx)
RU (1) RU2225221C2 (xx)
TR (1) TR200103788T2 (xx)
WO (1) WO2000061169A1 (xx)
ZA (1) ZA200109236B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
RU2225221C2 (ru) * 1999-04-09 2004-03-10 Орто-Макнейл Фармасьютикал, Инк. ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина
US7371787B2 (en) * 2000-04-14 2008-05-13 Viance, Llc Methods of incorporating treatment agents into wood based composite products
EP1525889A1 (en) † 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
JP4871720B2 (ja) * 2003-06-10 2012-02-08 エルジー ライフサイエンス リミテッド 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
BRPI0414699A (pt) * 2003-09-23 2006-11-28 Alcon Inc formulações de acetato de anecortave e acetonida de triancinolona para injeção
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
DE102004011663B4 (de) * 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US20050255112A1 (en) * 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CN101015684B (zh) * 2006-02-10 2011-08-24 华北制药集团新药研究开发有限责任公司 一种重组人红细胞生成素溶液制剂
US20080050749A1 (en) * 2006-08-17 2008-02-28 Ildiko Amann-Zalan Use of bnp-type peptides for the stratification of therapy with erythropoietic stimulating agents
ES2962777T3 (es) 2007-11-15 2024-03-21 Amgen Inc Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR100956431B1 (ko) 2007-12-07 2010-05-06 주식회사 제이에스마루 혈장크린접착제 및 이의 제조방법
MX346001B (es) 2008-09-26 2017-03-01 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
RS60226B1 (sr) 2012-09-07 2020-06-30 Coherus Biosciences Inc Stabilne vodene formulacije adalimumaba
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
BR112019025563A2 (pt) * 2017-06-06 2020-06-23 Kindred Biosciences, Inc. Eritropoietina e análogos para uso veterinário
CN111150837B (zh) * 2020-02-11 2022-07-12 中国人民解放军陆军军医大学 Epo在抗金黄色葡萄球菌感染药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5543575A (en) * 1990-06-20 1996-08-06 Pioneer-Hi-Bred International, Inc. Inbred corn line PHK46
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
RU2225221C2 (ru) * 1999-04-09 2004-03-10 Орто-Макнейл Фармасьютикал, Инк. ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина

Also Published As

Publication number Publication date
RU2225221C2 (ru) 2004-03-10
DE60039598D1 (de) 2008-09-04
WO2000061169A1 (en) 2000-10-19
ZA200109236B (en) 2003-12-08
AR029623A1 (es) 2003-07-10
TR200103788T2 (tr) 2002-05-21
CY1108418T1 (el) 2014-04-09
NO20014893D0 (no) 2001-10-08
US6696056B1 (en) 2004-02-24
CA2369444C (en) 2009-08-18
ATE401908T1 (de) 2008-08-15
US20040248797A1 (en) 2004-12-09
PL203797B1 (pl) 2009-11-30
CN1354669A (zh) 2002-06-19
NO20014893L (no) 2001-11-15
PL351837A1 (en) 2003-06-16
CN1165339C (zh) 2004-09-08
AU4218600A (en) 2000-11-14
HUP0201068A3 (en) 2002-10-28
ES2308978T3 (es) 2008-12-16
HUP0201068A2 (en) 2002-08-28
EP1181036A4 (en) 2004-04-21
KR100740794B1 (ko) 2007-07-20
KR20020016770A (ko) 2002-03-06
CA2369444A1 (en) 2000-10-19
DK1181036T3 (da) 2008-11-24
JP2002541208A (ja) 2002-12-03
MXPA01010208A (es) 2003-07-21
EP1181036A1 (en) 2002-02-27
NZ515380A (en) 2003-10-31
BR0010665A (pt) 2004-03-09
HK1041445B (zh) 2009-07-03
AU775041B2 (en) 2004-07-15
BG106046A (en) 2002-05-31
HK1041445A1 (en) 2002-07-12
EP1181036B1 (en) 2008-07-23
PT1181036E (pt) 2008-10-03

Similar Documents

Publication Publication Date Title
HUP0201068A3 (en) Pharmaceutical compositions of erythropoietin
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
PL351387A1 (en) Pharmaceutical composition
IL148864A0 (en) Pharmaceutical compositions containing nimesulide
HUP0203311A3 (en) New pharmaceutical compositions of prolonged effect
AU3556400A (en) Pharmaceutical compositions
GB9809213D0 (en) Pharmaceutical compositions
GB9904163D0 (en) Pharmaceutical compositions
AU4304400A (en) Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU6460400A (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
AU6460200A (en) Pharmaceutical compositions
GB9802472D0 (en) Pharmaceutical compositions
GB9904911D0 (en) Pharmaceutical compositions
AU6460300A (en) Pharmaceutical compositions
AU6460100A (en) Pharmaceutical compositions
IL149470A0 (en) Pharmaceutical compositions containing carboxamidoadenosine derivatives
IL130325A0 (en) Pharmaceutical compositions comprising allicin
GB9902651D0 (en) Pharmaceutical compositions
GB9806487D0 (en) Pharmaceutical compositions
GB9902591D0 (en) Pharmaceutical compositions
GB9920652D0 (en) Pharmaceutical compositions
GB9902594D0 (en) Pharmaceutical compositions